Trials / Recruiting
RecruitingNCT03708627
Bimatoprost as a Treatment for Graves' Orbitopathy
The Role of Bimatoprost in Graves' Periorbitopathy
- Status
- Recruiting
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 3 (estimated)
- Sponsor
- Johns Hopkins University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Testing whether Bimatoprost, a topical eye drop used for glaucoma, can be used to induce periorbital fat atrophy in patients with Graves' disease
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Bimatoprost Ophthalmic | Bimatoprost, aka Lumigan, one drop in one eye nightly |
Timeline
- Start date
- 2017-11-01
- Primary completion
- 2029-07-01
- Completion
- 2031-07-01
- First posted
- 2018-10-17
- Last updated
- 2025-07-17
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03708627. Inclusion in this directory is not an endorsement.